20/20 Biolabs (AIDX) vs NeoGenomics (NEO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
NeoGenomics is the larger company by market cap ($2.04 billion vs $4.8 million), about 425.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | AIDX | NEO |
|---|---|---|
| Share price | $0.375 | $15.85 |
| Market cap | $4.79M | $2.04B |
| 1-day change | +9.17% | -0.75% |
| YTD return | — | +35.80% |
| 1-year return | — | +76.85% |
| 5-year return | — | -63.19% |
| Forward P/E | — | 46.74 |
| EPS (TTM) | $-0.75 | $-0.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $50.00 | $20.15 |
| 52-week low | $0.33 | $7.07 |
| Distance from 52-week high | -99.25% | -21.34% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +35.96% |
| Average volume | 91.59K | 2.36M |
| Shares outstanding | 12.77M | 128.48M |
| Employees | — | 2,500 |
| Sector | Health Care | Health Care |
| Industry | Precision Instruments | Precision Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NeoGenomics is about 425.2 times larger than 20/20 Biolabs by market value ($2.04B vs $4.79M).
About NeoGenomics
NEO stock →NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom.
Health Care · Precision Instruments · 2,500 employees
AIDX vs NEO FAQ
Which is bigger, 20/20 Biolabs or NeoGenomics?
NeoGenomics (NEO) is larger, with a market capitalization of $2.04B compared with $4.79M for 20/20 Biolabs (AIDX).
Are 20/20 Biolabs and NeoGenomics in the same industry?
Yes. Both are classified in the Precision Instruments industry within the Health Care sector.